Jump to main content
Jump to site search

Issue 19, 2016
Previous Article Next Article

Peptide:glycosaminoglycan hybrid hydrogels as an injectable intervention for spinal disc degeneration

Author affiliations

Abstract

Degeneration of the spinal discs is a major cause of back pain. During the degeneration process, there is a loss of glycosaminoglycans (GAGs) from the proteoglycan-rich gel in the disc's nucleus, which adversely alters biomechanical performance. Current surgical treatments for back pain are highly invasive and have low success rates; there is an urgent need for minimally-invasive approaches that restore the physiological mechanics of the spine. Here we present an injectable peptide:GAG hydrogel that rapidly self-assembles in situ and restores the mechanics of denucleated intervertebral discs. It forms a gel with comparable mechanical properties to the native tissue within seconds to minutes depending on the peptide chosen. Unlike other biomaterials that have been proposed for this purpose, these hybrid hydrogels can be injected through a very narrow 25 G gauge needle, minimising damage to the surrounding soft tissue, and they mimic the ability of the natural tissue to draw in water by incorporating GAGs. Furthermore, the GAGs enhance the gelation kinetics and thermodynamic stability of peptide hydrogels, significantly reducing effusion of injected material from the intervertebral disc (GAG leakage of 8 ± 3% after 24 h when peptide present, compared to 39 ± 3% when no peptide present). In an ex vivo model, we demonstrate that the hydrogels can restore the compressive stiffness of denucleated bovine intervertebral discs. Compellingly, this novel biomaterial has the potential to transform the clinical treatment of back pain by resolving current surgical challenges, thus improving patient quality of life.

Graphical abstract: Peptide:glycosaminoglycan hybrid hydrogels as an injectable intervention for spinal disc degeneration

Back to tab navigation

Supplementary files

Publication details

The article was received on 15 Jan 2016, accepted on 29 Mar 2016 and first published on 29 Mar 2016


Article type: Paper
DOI: 10.1039/C6TB00121A
Citation: J. Mater. Chem. B, 2016,4, 3225-3231
  • Open access: Creative Commons BY license
  •   Request permissions

    Peptide:glycosaminoglycan hybrid hydrogels as an injectable intervention for spinal disc degeneration

    D. E. Miles, E. A. Mitchell, N. Kapur, P. A. Beales and R. K. Wilcox, J. Mater. Chem. B, 2016, 4, 3225
    DOI: 10.1039/C6TB00121A

    This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. Material from this article can be used in other publications provided that the correct acknowledgement is given with the reproduced material.

    Reproduced material should be attributed as follows:

    • For reproduction of material from NJC:
      [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the Centre National de la Recherche Scientifique (CNRS) and the RSC.
    • For reproduction of material from PCCP:
      [Original citation] - Published by the PCCP Owner Societies.
    • For reproduction of material from PPS:
      [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the European Society for Photobiology, the European Photochemistry Association, and RSC.
    • For reproduction of material from all other RSC journals:
      [Original citation] - Published by The Royal Society of Chemistry.

    Information about reproducing material from RSC articles with different licences is available on our Permission Requests page.

Search articles by author

Spotlight

Advertisements